AstraZeneca says its Covid shot still has role despite global glut
AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary with regard to transfer of securities effected during the year ended March 31, 2022. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- PRATAP RUDRADesignation :- Company Secretary and Compliance Officer ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated April 11, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to certify that, Integrated Registry Management Services Private Limited are the Company's Registrar and Transfer Agents and that all activities in relation to the share transfer are maintained by Integrated Registry Management Services Private Limited We are also attaching the certificate received from our Registrar and Transfer Agents, Integrated Registry Management Services Private Limited along with this letter. AstraZeneca rebrands its Global Technology Centrein Chennai
For digitally-enabled future, it has been rebranded as Global Innovation and Technology Centre ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
AstraZeneca Pharma India Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here ASTRAZENECA PHARMA INDIA LTD. - 506820 - Declaration Of Voting Results Of Postal Ballot
This is in reference to our letter dated February 23, 2022, enclosing therewith a Postal Ballot Notice dated February 8, 2022 seeking consent of Members of the Company through Ordinary Resolution for Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited. Pursuant to Regulation 44 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform that the said Resolution has been passed by Members of the Company with requisite majority. We are enclosing herewith the Voting Results along with the Scrutinizer's Report and the same are being placed on the Company's website at http://www.astrazeneca.com/india and website of National Securities Depository Limited at www.evoting.nsdl.com.